Search Results - "Jaeckle, Kurt A."

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial by GILBERT, Mark R, MEIHUA WANG, MAHAJAN, Anita, SCHULTZ, Christopher J, ERRIDGE, Sara, BAUMERT, Brigitta, HOPKINS, Kristen I, TZUK-SHINA, Tzahala, BROWN, Paul D, CHAKRAVARTI, Arnab, CURRAN, Walter J, MEHTA, Minesh P, ALDAPE, Kenneth D, STUPP, Roger, HEGI, Monika E, JAECKLE, Kurt A, ARMSTRONG, Terri S, WEFEL, Jeffrey S, MINHEE WON, BLUMENTHAL, Deborah T

“…Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA…”
Get full text

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma by Gilbert, Mark R, Dignam, James J, Armstrong, Terri S, Wefel, Jeffrey S, Blumenthal, Deborah T, Vogelbaum, Michael A, Colman, Howard, Chakravarti, Arnab, Pugh, Stephanie, Won, Minhee, Jeraj, Robert, Brown, Paul D, Jaeckle, Kurt A, Schiff, David, Stieber, Volker W, Brachman, David G, Werner-Wasik, Maria, Tremont-Lukats, Ivo W, Sulman, Erik P, Aldape, Kenneth D, Curran, Walter J, Mehta, Minesh P

“…The addition of bevacizumab to temozolomide and radiotherapy did not improve overall survival in patients with glioblastoma. Patients receiving bevacizumab had…”
Get full text

Liquid biopsy in gliomas: A RANO review and proposals for clinical applications by Soffietti, Riccardo, Bettegowda, Chetan, Mellinghoff, Ingo K, Warren, Katherine E, Ahluwalia, Manmeet S, De Groot, John F, Galanis, Evanthia, Gilbert, Mark R, Jaeckle, Kurt A, Le Rhun, Emilie, Rudà, Roberta, Seoane, Joan, Thon, Niklas, Umemura, Yoshie, Weller, Michael, van den Bent, Martin J, Vogelbaum, Michael A, Chang, Susan M, Wen, Patrick Y

“…There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring. The RANO…”
Get full text

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study by GALANIS, Evanthia, JAECKLE, Kurt A, RICHON, Victoria M, SCHEITHAUER, Bernd, GIANNINI, Caterina, FLYNN, Patrick J, MOORE, Dennis F, ZWIEBEL, James, BUCKNER, Jan C, MAURER, Matthew J, REID, Joel M, AMES, Matthew M, HARDWICK, James S, REILLY, John F, LOBODA, Andrey, NEBOZHYN, Michael, FANTIN, Valeria R

“…Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). Patients with recurrent GBM who had…”
Get full text

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study by Galanis, Evanthia, Buckner, Jan C, Maurer, Matthew J, Kreisberg, Jeffrey I, Ballman, Karla, Boni, J, Peralba, Josep M, Jenkins, Robert B, Dakhil, Shaker R, Morton, Roscoe F, Jaeckle, Kurt A, Scheithauer, Bernd W, Dancey, Janet, Hidalgo, Manuel, Walsh, Daniel J

“…Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against…”
Get full text

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 by Brown, Paul D, Krishnan, Sunil, Sarkaria, Jann N, Wu, Wenting, Jaeckle, Kurt A, Uhm, Joon H, Geoffroy, Francois J, Arusell, Robert, Kitange, Gaspar, Jenkins, Robert B, Kugler, John W, Morton, Roscoe F, Rowland, Jr, Kendrith M, Mischel, Paul, Yong, William H, Scheithauer, Bernd W, Schiff, David, Giannini, Caterina, Buckner, Jan C

“…Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance…”
Get full text

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074 by Uhm, Joon H., M.D, Ballman, Karla V., Ph.D, Wu, Wenting, Ph.D, Giannini, Caterina, M.D, Krauss, J.C., M.D, Buckner, Jan C., M.D, James, C.D., Ph.D, Scheithauer, Bernd W., M.D, Behrens, Robert J., M.D, Flynn, Patrick J., M.D, Schaefer, Paul L., M.D, Dakhill, Shaker R., M.D, Jaeckle, Kurt A., M.D

“…Purpose Amplification of the epidermal growth factor receptor (EGFR) gene represents one of the most frequent gene alterations in glioblastoma (GBM). In the…”
Get full text

Is There an Association Between Meningioma and Hormone Replacement Therapy? by BLITSHTEYN, Svetlana, CROOK, Julia E, JAECKLE, Kurt A

“…Molecular and clinical observations suggest a role of sex steroid hormones in the occurrence of meningioma. However, there is limited and often conflicting…”
Get full text

Pathway analysis of primary central nervous system lymphoma by Tun, Han W., Personett, David, Baskerville, Karen A., Menke, David M., Jaeckle, Kurt A., Kreinest, Pamela, Edenfield, Brandy, Zubair, Abba C., O'Neill, Brian P., Lai, Weil R., Park, Peter J., McKinney, Michael

“…Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS. A genome-wide gene expression comparison…”
Get full text

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme by Sarkaria, Jann N., M.D, Galanis, Evanthia, M.D, Wu, Wenting, Ph.D, Peller, Patrick J., M.D, Giannini, Caterina, M.D, Brown, Paul D., M.D, Uhm, Joon H., M.D, McGraw, Steven, M.D, Jaeckle, Kurt A., M.D, Buckner, Jan C., M.D

“…Background The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. On the basis of…”
Get full text

Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases by Jaeckle, Kurt A., Dixon, Jesse G., Anderson, Stephen Keith, Moreno‐Aspitia, Alvaro, Colon‐Otero, Gerardo, Hebenstreit, Kathy, Patel, Tejal A., Reddy, Samarth L., Perez, Edith A.

“…Background There are few treatment options for patients with leptomeningeal metastases (LM). Methods We report a case series of patients with breast cancer and…”
Get full text

Clinical features and outcomes in primary nervous system histiocytic neoplasms by Nathoo, Nabeela, Uhm, Joon H., Porter, Alyx B., Hammack, Julie, Jaeckle, Kurt A., Mrugala, Maciej M., Crum, Brian A., Flanagan, Eoin P., Pittock, Sean J., Goyal, Gaurav, Young, Jason R., Koster, Matthew J., Vassallo, Robert, Ryu, Jay H., Davidge-Pitts, Caroline J., Bach, Corrie, Ravindran, Aishwarya, Sartori Valinotti, Julio C., Bennani, N. Nora, Abeykoon, Jithma P., Shah, Mithun V., Hook, C. Christopher, Rech, Karen L., Go, Ronald S., Tobin, W. Oliver

Get full text

Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma by BROWN, Paul D, JENSEN, Ashley W, FELTEN, Sara J, BALLMAN, Karla V, SCHAEFER, Paul L, JAECKLE, Kurt A, CERHAN, Jane H, BUCKNER, Jan C

“…There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more…”
Get full text

Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study by JAECKLE, Kurt A, HESS, Kenneth R, CLOUGHESY, Timothy, NICHOLAS, M. Kelly, CHANG, Susan, PRADOS, Michael, YUNG, W. K, GREENBERG, Harry, FINE, Howard, SCHIFF, David, POLLACK, Ian F, KUHN, John, FINK, Karen, MEHTA, Minesh

“…Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG). This phase II trial…”
Get full text

Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response by Jaeckle, Kurt A, Ballman, Karla V, Rao, Ravi D, Jenkins, Robert B, Buckner, Jan C

“…Oligodendroglioma frequently (> or = 70%) responds to radiation and chemotherapy, and is the first CNS neoplasm in which a genetic signature (1p and 19q…”
Get full text

Neurological manifestations of neoplastic and radiation-induced plexopathies by Jaeckle, Kurt A

“…Metastatic plexopathy is often a disabling accompaniment of advanced systemic cancer and may involve any of the peripheral nerve plexuses. Brachial plexopathy…”
Get more information

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma by Tun, Han W., Johnston, Patrick B., DeAngelis, Lisa M., Atherton, Pamela J., Pederson, Levi D., Koenig, Patricia A., Reeder, Craig B., Omuro, Antonio M. Padula, Schiff, David, O'Neill, Brian, Pulido, Jose, Jaeckle, Kurt A., Grommes, Christian, Witzig, Thomas E.

“…The combination of pomalidomide (POM) and dexamethasone (DEX) was evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL) and primary…”
Get full text

Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination α-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas by LEVIN, Victor A, HESS, Kenneth R, GLEASON, Mary Jo, KIM, Hyung-Woo, CHOUCAIR, Ali, FLYNN, Patrick J, JAECKLE, Kurt A, KYRITSIS, Athanassios P, YUNG, W. K, PRADOS, Michael D, BRUNER, Janet M, ICTECH, Sandra

“…Purpose: In the current study, we sought to determine whether the addition of DFMO (α-difluoromethyl ornithine; eflornithine), an inhibitor of ornithine…”
Get full text

Oligodendroglial Tumors by Jaeckle, Kurt A

“…Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than…”
Get full text

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design by Jaeckle, Kurt A, Ballman, Karla V, van den Bent, Martin, Giannini, Caterina, Galanis, Evanthia, Brown, Paul D, Jenkins, Robert B, Cairncross, J Gregory, Wick, Wolfgang, Weller, Michael, Aldape, Kenneth D, Dixon, Jesse G, Anderson, S Keith, Cerhan, Jane H, Wefel, Jeffrey S, Klein, Martin, Grossman, Stuart A, Schiff, David, Raizer, Jeffrey J, Dhermain, Frederick, Nordstrom, Donald G, Flynn, Patrick J, Vogelbaum, Michael A

“…Abstract Background We report the analysis involving patients treated on the initial CODEL design. Methods Adults (>18) with newly diagnosed 1p/19q World…”
Get full text